Literature DB >> 23258962

Lucinactant: new and approved, but is it an improvement?

Sandra S Garner1, Toby H Cox.   

Abstract

Year:  2012        PMID： 23258962      PMCID： PMC3526923          DOI： 10.5863/1551-6776-17.3.206

Source DB:  PubMed          Journal:  J Pediatr Pharmacol Ther        ISSN： 1551-6776


× No keyword cloud information.
  17 in total

1.  Synthetic surfactants: the search goes on.

Authors:  John Kattwinkel
Journal:  Pediatrics       Date:  2005-04       Impact factor: 7.124

2.  Comparative effects of some serum components and proteolytic products of fibrinogen on surface tension-lowering abilities of beractant and a synthetic peptide containing surfactant KL4.

Authors:  E Manalo; T A Merritt; A Kheiter; J Amirkhanian; C Cochrane
Journal:  Pediatr Res       Date:  1996-06       Impact factor: 3.756

3.  A multicenter, randomized, masked, comparison trial of lucinactant, colfosceril palmitate, and beractant for the prevention of respiratory distress syndrome among very preterm infants.

Authors:  Fernando R Moya; Janusz Gadzinowski; Eduardo Bancalari; Vicente Salinas; Benjamin Kopelman; Aldo Bancalari; Maria Katarzyna Kornacka; T Allen Merritt; Robert Segal; Christopher J Schaber; Huei Tsai; Joseph Massaro; Ralph d'Agostino
Journal:  Pediatrics       Date:  2005-04       Impact factor: 7.124

4.  A multicenter, randomized, controlled trial of lucinactant versus poractant alfa among very premature infants at high risk for respiratory distress syndrome.

Authors:  Sunil K Sinha; Thierry Lacaze-Masmonteil; Adolf Valls i Soler; Thomas E Wiswell; Janusz Gadzinowski; Julia Hajdu; Graham Bernstein; Manuel Sanchez-Luna; Robert Segal; Christopher J Schaber; Joseph Massaro; Ralph d'Agostino
Journal:  Pediatrics       Date:  2005-04       Impact factor: 7.124

5.  Caffeine therapy for apnea of prematurity.

Authors:  Barbara Schmidt; Robin S Roberts; Peter Davis; Lex W Doyle; Keith J Barrington; Arne Ohlsson; Alfonso Solimano; Win Tin
Journal:  N Engl J Med       Date:  2006-05-18       Impact factor: 91.245

6.  A pharmacoeconomic analysis of in-hospital costs resulting from reintubation in preterm infants treated with lucinactant, beractant, or poractant alfa.

Authors:  Carlos G Guardia; Fernando R Moya; Sunil Sinha; Phillip D Simmons; Robert Segal; Jay S Greenspan
Journal:  J Pediatr Pharmacol Ther       Date:  2012-07

7.  Nasal CPAP or intubation at birth for very preterm infants.

Authors:  Colin J Morley; Peter G Davis; Lex W Doyle; Luc P Brion; Jean-Michel Hascoet; John B Carlin
Journal:  N Engl J Med       Date:  2008-02-14       Impact factor: 91.245

Review 8.  Early surfactant administration with brief ventilation vs. selective surfactant and continued mechanical ventilation for preterm infants with or at risk for respiratory distress syndrome.

Authors:  T P Stevens; E W Harrington; M Blennow; R F Soll
Journal:  Cochrane Database Syst Rev       Date:  2007-10-17

9.  One-year follow-up of very preterm infants who received lucinactant for prevention of respiratory distress syndrome: results from 2 multicenter randomized, controlled trials.

Authors:  Fernando Moya; Sunil Sinha; Janusz Gadzinowski; Ralph D'Agostino; Robert Segal; Carlos Guardia; Jan Mazela; Genzhou Liu
Journal:  Pediatrics       Date:  2007-05-28       Impact factor: 7.124

10.  Surfactant-replacement therapy for respiratory distress in the preterm and term neonate.

Authors:  William A Engle
Journal:  Pediatrics       Date:  2008-02       Impact factor: 7.124
View more
  1 in total

1.  MultiPep: a hierarchical deep learning approach for multi-label classification of peptide bioactivities.

Authors:  Alexander G B Grønning; Tim Kacprowski; Camilla Schéele
Journal:  Biol Methods Protoc       Date:  2021-11-23
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.